Literature DB >> 10534141

Nitric oxide modulates HIV-1 replication.

J B Mannick1, J S Stamler, E Teng, N Simpson, J Lawrence, J Jordan, R W Finberg.   

Abstract

Although nitric oxide (NO) production is increased in HIV-1-infected patients, and NO is known to inhibit the replication of several viruses, very little is known about the effects of NO on HIV-1 replication. In the present studies, we find that S-nitrosothiols (RSNOs), a class of NO donor compounds present in the human circulatory system, inhibit HIV-1 replication in acutely infected human peripheral blood mononuclear cells (PBMCs) and have an additive inhibitory effect on HIV-1 replication in combination with 3'-azido-3'-deoxythymidylate (AZT). RSNOs inhibit HIV-1 replication in acutely infected PBMCs at a step in the viral replicative cycle after reverse transcription, but before or during viral protein expression through a cGMP-independent mechanism. In the latently infected U1 cell line, NO donor compounds and intracellular NO production stimulate HIV-1 reactivation. These studies suggest that NO both inhibits HIV-1 replication in acutely infected cells and stimulates HIV-1 reactivation in chronically infected cells. Thus, NO may have a physiologic role in HIV-1 replication, and NO donor compounds, which have been used for decades in the treatment of coronary artery disease with limited toxicity, might be useful in the treatment of HIV-1 disease by inhibiting acute infection, reactivating latent virus, or both.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534141     DOI: 10.1097/00042560-199909010-00001

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

2.  Regulation of human immunodeficiency virus type 1 replication in human T lymphocytes by nitric oxide.

Authors:  J L Jiménez; J González-Nicolás; S Alvarez; M Fresno; M A Muñoz-Fernández
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  U1 and OM10.1. Myeloid Cell Lines as Surrogate Models of Reversible Proviral Latency.

Authors:  Guido Poli
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.

Authors:  Moran Benhar; Iart Luca Shytaj; Jonathan S Stamler; Andrea Savarino
Journal:  J Clin Invest       Date:  2016-05-02       Impact factor: 14.808

5.  Peroxynitrite inhibition of Coxsackievirus infection by prevention of viral RNA entry.

Authors:  Elizaveta Padalko; Tomokazu Ohnishi; Kenji Matsushita; Henry Sun; Karen Fox-Talbot; Clare Bao; William M Baldwin; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-30       Impact factor: 11.205

6.  The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.

Authors:  Marc C E Wagner
Journal:  Curr HIV Res       Date:  2011-06       Impact factor: 1.581

7.  Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study.

Authors:  Peace D Imani; Philippa Musoke; Justus Byarugaba; James K Tumwine
Journal:  BMC Pediatr       Date:  2011-01-14       Impact factor: 2.125

8.  Commentary: mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma.

Authors:  Chad M Thompson; Roland C Grafström
Journal:  Environ Health       Date:  2009-11-25       Impact factor: 5.984

9.  Activation of HIV-1 expression and replication by cGMP dependent protein kinase type 1-beta (PKG1beta).

Authors:  Jia Hai Lee; Venkat Rk Yedavalli; Kuan-Teh Jeang
Journal:  Retrovirology       Date:  2007-12-13       Impact factor: 4.602

10.  Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.

Authors:  Ajay Wanchu; Archana Bhatnagar; Madhu Khullar; Archana Sud; Pradeep Bambery; Surjit Singh
Journal:  BMC Infect Dis       Date:  2002-07-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.